Handling work for banks as underwriters, O’Melveny has continued to forge a particularly impressive furrow advising China-based technology and life sciences/healthcare companies seeking to list on the HKSE and in the US. Key to the firm’s success in the area is the work of Ke Geng whose biochemistry phD ensures he is able to provide added insight on deals in the sector, including a large proportion of the 18A listings in Hong Kong. Geng is noted for his ‘solutions-oriented approach’, which also ensures that he is appreciated by clients seeking to execute “first-of-kind” transactions, including his recent work alongside PRC and US practitioners for life sciences company Adlai Nortye, the first US IPO of a China-originated company since the CSRC adopted new measures.
Testimonials
Collated independently by Legal 500 research team.
‘Ke Geng has rich project experience and excels in solving complex problems with a solutions-oriented approach. He works conscientiously and efficiently, and has outstanding professional ability and good communication skills.'
Key clients
- FOLANGSI CO.
- Beijing UBOX Online Technology Corp.
Work highlights
- Represented Tian Tu Capital in its approximately HK$1.13bn IPO and listing of H shares in Hong Kong, the first-ever listing of a PRC VC firm on the Main Board of the Hong Kong Stock Exchange.
- Represented Adlai Nortye in its IPO on the Nasdaq, the first US IPO of a China-originated company since the China Securities Regulatory Commission (CSRC) adopted new measures.